Statins May Lower Rates of Prostate Cancer Recurrence
Reviewed By
Rating
Statins May Lower Rates of Prostate Cancer Recurrence
Our Review Summary
A relatively clear breakdown of the unclear picture of whether statins may help in this specific area of research.
Why This Matters
One thing that made this story better than its WebMD competition was the expert source who put this study in the context of other studies that have been done and raised questions about statistical problems in the study (although we wish we’d heard more about this).
Criteria
Satisfactory
The story says statins can cost $5 a day or more.
Not Satisfactory
Only relative risk reduction figures were used. So when the story said "30% less likely" – readers need to know "30% of what?"
Satisfactory
The story explained that statins may cause liver problems and muscle damage, "although the likelihood of that is low."
Satisfactory
The story raised ample questions about the quality of the evidence.
Satisfactory
No disease mongering was evident.
Satisfactory
The senior study author and one independent expert were quoted.
Satisfactory
The alternative of NOT taking statins was raised: "However, not every prostate cancer patient may need to take them."
Satisfactory
The story states that "statins are among the most widely prescribed drugs in America."
Satisfactory
The story explained that there has been prior conflicting research on this question.
Satisfactory
Because of multiple sources quoted, it does not appear that the story relied on a news release.
Total Score: 9 of 10 Satisfactory
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like